Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L)

• Published in: Journal of thrombosis and haemostasis Vol. 13; no. 9; p. 1694
• Main Authors: George, L A, Thalji, N K, Raffini, L J, Gimotty, P A, Camire, R M
• Format: Journal Article
• Language: English
• Published: England 01.09.2015
• Subjects: Blood Coagulation - drug effects; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Factor VIIa - pharmacology; Factor VIII - immunology; Factor Xa - pharmacology; Hemophilia A - blood; Hemophilia A - drug therapy; Hemophilia A - immunology; Hemostatics - pharmacology; Humans; Isoantibodies - immunology; Male; Mutagenesis, Site-Directed; Recombinant Proteins - pharmacology; Thrombelastography; Time Factors; coagulation time, whole blood; factor X, activated; deficiency, factor VIII; hemophilia A, congenital; hemophilia B; inhibitor, blood coagulation factor

Approximately 30% of hemophilia A (HA) and 5% of hemophilia B patients develop inhibitors to protein replacement therapy, and this is the major cause of disease-related morbidity in the developed world. We previously developed zymogen-like factor Xa (FXa) molecules with impaired active site maturati...